Article ID Journal Published Year Pages File Type
8234094 International Journal of Radiation Oncology*Biology*Physics 2009 7 Pages PDF
Abstract
Patients with HPV+ OPSCC have an excellent prognosis after radiochemotherapy, but cisplatin-based chemotherapy may not confer a satisfactory outcome, especially in WT cases, thereby justifying the additional or alternative use of taxanes and epidermal growth factor receptors inhibitors. Uncommon distant metastases and second tumors in the HPV+ group may be cause for clinicians to review the follow-up policies in these patients.
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Authors
, , , , , , , , ,